INFO:
Data presented at a press conference during the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna Dr Luis Paz-Ares explained tha
Sorafenib does not extend overall survival as third or fourth line therapy in lung cancer – Phase III MISSION trial - ecancer